Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies.
Pascal L, Mohty M, Ruggeri A, Tucunduva L, Milpied N, Chevallier P, Tabrizi R, Labalette M, Gluckman E, Labopin M, Yakoub-Agha I. Pascal L, et al. Among authors: tabrizi r. Bone Marrow Transplant. 2015 Jan;50(1):45-50. doi: 10.1038/bmt.2014.216. Epub 2014 Oct 20. Bone Marrow Transplant. 2015. PMID: 25330221 Clinical Trial.
Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Detrait MY, Morisset S, Peffault de Latour R, Yakoub-Agha I, Crocchiolo R, Tabrizi R, Bay JO, Chevalier P, Barraco F, Raus N, Vigouroux S, Magro L, Mohty M, Milpied N, Blaise D, Socié G, Michallet M. Detrait MY, et al. Among authors: tabrizi r. Bone Marrow Transplant. 2015 Feb;50(2):253-8. doi: 10.1038/bmt.2014.244. Epub 2014 Nov 3. Bone Marrow Transplant. 2015. PMID: 25365068
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT). Passweg JR, et al. Among authors: tabrizi r. Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121. Epub 2015 Jun 1. Bone Marrow Transplant. 2015. PMID: 26030052 Clinical Trial.
Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy.
Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, Contentin N, Mohty M, Nguyen S, Lioure B, Raus N, Peffault de Latour R, Yakoub-Agha I, Reman O; SFGM-TC group. Chantepie SP, et al. Among authors: tabrizi r. Bone Marrow Transplant. 2015 Dec;50(12):1586-8. doi: 10.1038/bmt.2015.206. Epub 2015 Sep 14. Bone Marrow Transplant. 2015. PMID: 26367219 No abstract available.
Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.
Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, Michallet M, Santarone S, Ehninger G, Polge E, Laszlo D, Schmid C, Nagler A, Mohty M. Andreola G, et al. Among authors: tabrizi r. Bone Marrow Transplant. 2015 Dec;50(12):1508-12. doi: 10.1038/bmt.2015.193. Epub 2015 Sep 21. Bone Marrow Transplant. 2015. PMID: 26389832
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, Guillaume T, Vigouroux S, El-Cheikh J, Delaunay J, Le Gouill S, Moreau P, Labopin M, Chevallier P. Mohty M, et al. Among authors: tabrizi r. Cancer. 2015 Feb 15;121(4):562-9. doi: 10.1002/cncr.29087. Epub 2014 Oct 3. Cancer. 2015. PMID: 25283774 Free article. Clinical Trial.
Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.
Mohty M, Malard F, Blaise D, Milpied N, Socié G, Huynh A, Reman O, Yakoub-Agha I, Furst S, Guillaume T, Tabrizi R, Vigouroux S, Peterlin P, El-Cheikh J, Moreau P, Labopin M, Chevallier P. Mohty M, et al. Among authors: tabrizi r. Haematologica. 2017 Jan;102(1):184-191. doi: 10.3324/haematol.2016.150326. Epub 2016 Aug 25. Haematologica. 2017. PMID: 27561720 Free PMC article. Clinical Trial.
Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response.
Robles M, Vigouroux S, Tabrizi R, Bouabdallah K, Dilhuydy MS, Parrens M, Leguay T, Pigneux A, Dumas PY, Lascaux A, Duclos C, Marit G, Milpied N. Robles M, et al. Among authors: tabrizi r. Bone Marrow Transplant. 2013 Nov;48(11):1484-5. doi: 10.1038/bmt.2013.86. Epub 2013 Jun 3. Bone Marrow Transplant. 2013. PMID: 23727750 No abstract available.
Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J, Maillard N, Tabrizi R, Choquet S, Carras S, Ifrah N, Guillerm G, Mohty M, Tilly H, Socie G, Cornillon J, Hermine O, Daguindau É, Bachy E, Girault S, Marchand T, Oberic L, Reman O, Leux C, Le Gouill S. Tessoulin B, et al. Among authors: tabrizi r. Bone Marrow Transplant. 2016 Sep;51(9):1184-90. doi: 10.1038/bmt.2016.102. Epub 2016 Apr 25. Bone Marrow Transplant. 2016. PMID: 27111043
376 results